Premium
Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs
Author(s) -
Armstrong Katrina,
Kim Jane J.,
Halm Ethan A.,
Ballard Rachel M.,
Schnall Mitchell D.
Publication year - 2016
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29937
Subject(s) - medicine , cancer , cancer screening , breast cancer , population , lung cancer screening , family medicine , cervical cancer , colorectal cancer , lung cancer , health care , breast cancer screening , medical physics , intensive care medicine , gynecology , oncology , mammography , environmental health , economics , economic growth
Multiple advisory groups now recommend that high‐risk smokers be screened for lung cancer by low‐dose computed tomography. Given that the development of lung cancer screening programs will face many of the same issues that have challenged other cancer screening programs, the National Cancer Institute‐funded Population‐based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium was used to identify lessons learned from the implementation of breast, cervical, and colorectal cancer screening that should inform the introduction of lung cancer screening. These lessons include the importance of developing systems for identifying and recruiting eligible individuals in primary care, ensuring that screening centers are qualified and performance is monitored, creating clear communication standards for reporting screening results to referring physicians and patients, ensuring follow‐up is available for individuals with abnormal test results, avoiding overscreening, remembering primary prevention, and leveraging advances in cancer genetics and immunology. Overall, this experience emphasizes that effective cancer screening is a multistep activity that requires robust strategies to initiate, report, follow up, and track each step as well as a dynamic and ongoing oversight process to revise current screening practices as new evidence regarding screening is created, new screening technologies are developed, new biological markers are identified, and new approaches to health care delivery are disseminated. Cancer 2016;122:1338–1342 . © 2016 American Cancer Society .